HK1197083A1 - Regulation of receptor expression through delivery of artificial transcription factors - Google Patents

Regulation of receptor expression through delivery of artificial transcription factors Download PDF

Info

Publication number
HK1197083A1
HK1197083A1 HK14110571.0A HK14110571A HK1197083A1 HK 1197083 A1 HK1197083 A1 HK 1197083A1 HK 14110571 A HK14110571 A HK 14110571A HK 1197083 A1 HK1197083 A1 HK 1197083A1
Authority
HK
Hong Kong
Prior art keywords
thr
glu
lys
ser
gly
Prior art date
Application number
HK14110571.0A
Other languages
English (en)
Chinese (zh)
Inventor
Josef Flammer
Albert NEUTZNER
Alice Huxley
Original Assignee
Aliophtha Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aliophtha Ag filed Critical Aliophtha Ag
Publication of HK1197083A1 publication Critical patent/HK1197083A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HK14110571.0A 2011-10-11 2012-10-10 Regulation of receptor expression through delivery of artificial transcription factors HK1197083A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11184706 2011-10-11
EP11184706.7 2011-10-11
PCT/EP2012/069981 WO2013053719A2 (en) 2011-10-11 2012-10-10 Regulation of receptor expression through delivery of artificial transcription factors

Publications (1)

Publication Number Publication Date
HK1197083A1 true HK1197083A1 (en) 2015-01-02

Family

ID=47045011

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14110571.0A HK1197083A1 (en) 2011-10-11 2012-10-10 Regulation of receptor expression through delivery of artificial transcription factors

Country Status (21)

Country Link
US (1) US20140296129A1 (https=)
EP (1) EP2766484A2 (https=)
JP (1) JP2014530607A (https=)
KR (1) KR20140079780A (https=)
CN (1) CN103998609A (https=)
AU (1) AU2012323032A1 (https=)
BR (1) BR112014008456A2 (https=)
CA (1) CA2851560A1 (https=)
CL (1) CL2014000897A1 (https=)
CO (1) CO6930308A2 (https=)
EA (1) EA201490531A1 (https=)
HK (1) HK1197083A1 (https=)
IL (1) IL231865A0 (https=)
IN (1) IN2014CN02586A (https=)
MA (1) MA36970A1 (https=)
MX (1) MX2014004331A (https=)
PH (1) PH12014500786A1 (https=)
SG (1) SG11201400701WA (https=)
TN (1) TN2014000117A1 (https=)
WO (1) WO2013053719A2 (https=)
ZA (1) ZA201401960B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
WO2019195285A1 (en) * 2018-04-02 2019-10-10 University Of Miami Ifn-beta reporter system for immortalized primary cells
CN114206396A (zh) 2019-05-28 2022-03-18 西莱克塔生物科技公司 用于减弱抗病毒转移载体免疫应答的方法和组合物
EP4075980B1 (en) 2019-12-18 2025-07-23 Stinginn LLC Substituted 1,2, 4-triazoles and methods of use
CN111304314B (zh) * 2020-02-25 2020-11-20 四川省人民医院 Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用
US20220049310A1 (en) * 2020-02-25 2022-02-17 Sichuan Provincial People's Hospital Use of ZNF124 Gene in Early Screening or Auxiliary Diagnosis of Retinitis Pigmentosa Disease
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39229E1 (en) * 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
AU2964101A (en) * 2000-01-21 2001-07-31 Scripps Research Institute, The Methods and compositions to modulate expression in plants
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
NZ527476A (en) * 2001-02-21 2006-06-30 Novartis Ag Zinc finger binding domains for nucleotide sequence ANN
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
WO2007041218A2 (en) * 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of tool-like receptors on stem cells
WO2008140538A1 (en) * 2006-10-04 2008-11-20 Verenium Corporation Dna display screen for expression product with desired binding properties
GB0620705D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
CN101333251A (zh) * 2008-01-30 2008-12-31 中国人民解放军第三军医大学 能启动a20基因表达的人工锌指蛋白转录因子及用途
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
JP2012521766A (ja) * 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた高親和性ＩｇＥ受容体α鎖（ＦＣεＲ１α）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2509594A1 (en) * 2009-12-09 2012-10-17 INSERM - Institut National de la Santé et de la Recherche Médicale Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis

Also Published As

Publication number Publication date
SG11201400701WA (en) 2014-08-28
EA201490531A1 (ru) 2014-08-29
WO2013053719A2 (en) 2013-04-18
BR112014008456A2 (pt) 2017-04-11
CL2014000897A1 (es) 2014-11-21
CN103998609A (zh) 2014-08-20
TN2014000117A1 (en) 2015-07-01
KR20140079780A (ko) 2014-06-27
US20140296129A1 (en) 2014-10-02
IL231865A0 (en) 2014-05-28
WO2013053719A3 (en) 2013-06-27
EP2766484A2 (en) 2014-08-20
CO6930308A2 (es) 2014-04-28
MX2014004331A (es) 2014-11-26
CA2851560A1 (en) 2013-04-18
MA36970A1 (fr) 2016-03-31
PH12014500786A1 (en) 2021-08-09
AU2012323032A1 (en) 2014-04-03
ZA201401960B (en) 2015-06-24
IN2014CN02586A (https=) 2015-08-07
JP2014530607A (ja) 2014-11-20

Similar Documents

Publication Publication Date Title
HK1197083A1 (en) Regulation of receptor expression through delivery of artificial transcription factors
JP7177047B2 (ja) ポリペプチドカーゴを標的真核細胞の細胞外間隙からサイトゾルおよび／または核に送達するための合理的に設計された合成ペプチドシャトル剤、その使用、それに関連する方法およびキット
KR100937550B1 (ko) Ｏｂ 융합 단백질 조성물과 이 단백질의 제조 방법
US6054436A (en) Regulated apoptosis
AU763755B2 (en) OB fusion protein compositions and methods
CN108350467B (zh) 基因构建体
HUT73100A (en) Regulated apoptosis
CZ302303B6 (cs) Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor
HUT73101A (en) Method for regulating transcription of targeted genes and other biological events
US20030027314A1 (en) Extension of a protein-protein interaction surface to inactivate the function of a cellular protein
CN108473546A (zh) Mg53突变体及其制备方法和用途
CN109689086A (zh) 具有延长的血清半衰期的融合蛋白
JPH08503858A (ja) 生物活性ポリペプチド融合ダイマー
JP2016515596A (ja) Ｏｐａ１ハプロ不全に起因する疾患の治療のための人工転写因子
JP2020072716A (ja) 細胞透過組成物およびそれを用いる方法
US6891021B2 (en) Regulated apoptosis
EP1605964B1 (en) TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE
CN116802301A (zh) Tnfr2与april/baff受体的融合蛋白
JP4686780B2 (ja) 細胞死抑制活性強化タンパク質ｆｎｋを用いた脱毛の防止
JP5858402B2 (ja) アレルギー性疾患治療薬
US20160039892A1 (en) Artificial transcription factors and their use for the treatment of maladapted wound healing in the eye
EP0879884A2 (en) Novel CD4 derivatives
MXPA99005780A (en) Ob fusion protein compositions and methods
NZ524612A (en) OB fusion protein compositions and methods